Dengue is the most rapidly spreading disease caused by a mosquito-borne virus in the world. The incidence of dengue globally has increased 30-fold in the last 50 years. Understanding the prevalence of dengue and its longitudinal trends can improve prevention and control strategies. This study assessed the trends in prevalence of dengue in Taiwan by population characteristics and geographical region. Dengue and population data for the years 2010-2015 were obtained from the public statistics databases of the Taiwan Centers for Disease Control and Department of Statistics, Taiwan Ministry of Interior. Yearly prevalence rates of dengue were calculated by age group, sex, and administrative area within five geographic regions (northern, mid-western, southern, and eastern regions, and outer islands). The national prevalence rate of dengue decreased gradually from 8 to 4 per 100000 population between 2010 and 2013, but it increased substantially in 2014 and 2015 to 67 and 187 per 100000 population, respectively. There was no significant difference in prevalence rate between males and females. People aged 60-69 years had a significantly higher prevalence rate than those in the other age groups during 2010-2014, and people aged over 70 years had the highest rate in 2015 (309 per 100000 population). The southern region had the highest yearly dengue prevalence rate (the rate decreased from 23 to 9 per 100000 population between 2010 and 2013, but increased to 220 and 616 per 100000 population in 2014 and 2015, respectively). Three unexpected outbreaks of dengue were observed during the study period: the first outbreak occurred in Penghu County in 2011 (prevalence rate 101 per 100000 population), the second in Kaohsiung City in 2014 (prevalence rate 540 per 100000 population), and the third in Tainan City in 2015 (prevalence rate 1208 per 100000 population). More efforts are still needed to prevent and control dengue in Taiwan. The government should direct resources and interventions to southern Taiwan, which has a tropical climate and a high population density, and should target older people who are more likely to be infected. Strategies are also needed to respond quickly to unexpected incidents to prevent dengue outbreaks.

Objective Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011. Design This is a retrospective observational study focusing on the utilisation of statins. Setting The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan’s National Health Insurance Research Database. Main outcome measures We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. Results The number of statin users increased from 10 299 (~1.4% of adults) in 2002 to 50 687 (~6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%–36.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007–2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002–2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.

Background The rapid growth of health care expenditures, especially pharmaceutical spending, is a challenge for many countries. To control increasing pharmaceutical expenditures and to enhance rational use of drugs, Taiwan’s National Health Insurance drug reimbursement system has evolved over time since its introduction in 1995. This study reviewed Taiwan’s drug reimbursement scheme: its development and evolution in the last two decades, and implications and impacts of recent policies for drug pricing. We also provide recommendations for possible improvement. Methods We conducted a review of Taiwan’s National Health Insurance drug reimbursement scheme. We focused on three major components of the scheme: (i) the scope of drug coverage; (ii) pricing system for pharmaceuticals under the scheme; and (iii) adjustment of drug reimbursement prices. We reviewed the literature and public policy documents. Results The National Health Insurance delisted 176 and another 240 behind-the-counter products (e.g., antacids, vitamins) between 2005 and 2006 to reduce pharmaceutical expenditures. For the pricing of pharmaceuticals, policy evolution can be divided into four phases since 1995; the present system emphasizes stakeholder engagement, health technology assessment, domestic R&D, and improving quality of products. To close the gap between drug reimbursement prices and procurement prices, eight rounds of drug price surveys and adjustments have been implemented since 2000. Conclusions Taiwan’s National Health Insurance drug reimbursement scheme has evolved substantially over time to provide more equitable and affordable access to prescription medicines. However, more work is still needed as irrational difference in reimbursement and procurement prices persists and the total expenditure of the drug reimbursement scheme continues to increase at unsustainable rates.

High-cost orphan drugs are becoming increasingly available to treat rare diseases that affect a relatively small population. Little attention has been given to the prevalence of rare diseases and their health-related economic burden in Taiwan. This study examined the national trends in the prevalence of rare diseases and their health-related economic burden (including medication costs) in Taiwan. Rare disease-related claims data from 2003–2014 (12 years) from the National Health Insurance Research Database were used in this study. We used a time series analysis to assess trends in the yearly rates of treated patients with rare diseases, overall healthcare use, and expenditures, including drugs. During the 12-year study period, the estimated prevalence of rare diseases increased from 10.57 to 33.21 per 100,000 population, an average rate of a 19.46% increase per year. Total health expenditures for treatment of rare diseases increased from US$18.65 million to US$137.44 million between 2003 and 2014, accounting for 0.68% of the total national health expenditures in 2014. Drug expenditures for treatment of rare diseases increased from US$13.24 million to US$121.98 million between 2003 and 2014, which accounted for 71.00% and 88.75% of the health expenditures for patients with rare diseases in 2003 and 2014, respectively. In 2014, we found a 20.43-fold difference in average health expenditures and a 69.46-fold difference in average drug expenditures between patients with rare diseases and the overall population. The prevalence of rare diseases and the related economic burden have grown substantially in Taiwan over the past 12 years, and these trends are likely to continue. Drug expenditures accounted for almost 90% of health expenditures for rare diseases. Further analyses are underway to examine the economic burden of individual rare diseases.

Introduction: Pancreatic cancer is associated with poor prognosis. Considering the increased global incidence of diabetes cases and that individuals with diabetes are considered a high‐risk subpopulation for pancreatic cancer, it is critical to detect the risk of pancreatic cancer within populations of person living = with diabetes. This study aimed to develop a novel prediction model for pancreatic cancer risk among patients with diabetes, using = a real‐world database containing clinical features and employing numerous artificial intelligent approach algorithms.Methods: This retrospective observational study analyzed data on patients with Type 2 diabetes from a multisite Taiwanese EMR database between 2009 and 2019. Predictors were selected in accordance with the literature review and clinical perspectives. The prediction models were constructed using machine learning algorithms such as logistic regression, linear discriminant analysis, gradient boosting machine, and random forest.Results: The cohort consisted of 66,384 patients. The Linear Discriminant Analysis (LDA) model generated the highest AUROC of 0.9073, followed by the Voting Ensemble and Gradient Boosting machine models. LDA, the best model, exhibited an accuracy of 84.03%, a sensitivity of 0.8611, and a specificity of 0.8403. The most significant predictors identified for pancreatic cancer risk were glucose, glycated hemoglobin, hyperlipidemia comorbidity, antidiabetic drug use, and lipid‐modifying drug use.Conclusion: This study successfully developed a highly accurate 4‐year risk model for pancreatic cancer in patients with diabetes using real‐world clinical data and multiple machine‐learning algorithms. Potentially, our predictors offer an opportunity to identify pancreatic cancer early and thus increase prevention and invention windows to impact survival in diabetic patients.